Trials / Completed
CompletedNCT00244725
Odiparcil For The Prevention Of Venous Thromboembolism
A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 961 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Odiparcil | |
| DRUG | Warfarin | |
| DRUG | Coumadin |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2005-10-27
- Last updated
- 2017-05-02
- Results posted
- 2017-05-02
Locations
101 sites across 13 countries: United States, Australia, Brazil, Canada, India, Israel, Latvia, Lithuania, Poland, Russia, South Africa, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00244725. Inclusion in this directory is not an endorsement.